Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5141]

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Anastrazole offers higher breast cancer-free survival rates than tamoxifen...

Prof Richard Margolese - The Jewish General Hospital, McGill University...

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )

Eribulin extends overall survival for patients with advanced liposarcoma and...

Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

Extensive lymph node surgery may not be necessary for some patients with...

Prof Claus Garbe - University of Tübingen, Tübingen, Germany.

Extensive lymph node surgery may not be necessary for some patients with melanoma ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany. )

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.

First effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA. )

Novel JAK inhibitor pacritinib proves effective for easing symptoms of...

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

New ibrutinib combination regimen shows substantial benefits in relapsed...

Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA

New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )

Obinutuzumab doubles remission duration in patients with relapsed, indolent non...

Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )

First-in-class targeted drug daratumumab shows promise in heavily treatment...

Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )

Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse...

Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA

Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction ( Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA )

Pembrolizumab for head and neck cancer

Dr Tanguy Seiwert - University of Chicago, Chicago, USA

Pembrolizumab for head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )

Pembrolizumab shows promising activity against head and neck cancer

Dr Tanguy Seiwert - University of Chicago, Chicago, USA

Pembrolizumab shows promising activity against head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )

More from ecancer